Exploring Infinite Possibilities in Regenerative Anti-Aging: Xihong Pharma Showcases Core Technologies at AMWC World Congress

From October 20 to 22, the highly anticipated 3rd AMWC China World Aesthetic & Anti-Aging Medicine Congress was grandly held at the Tianfu International Conference Center in Chengdu. The event brought together numerous industry leaders, focusing on trending topics in anti-aging and showcasing cutting-edge anti-aging products and advanced aesthetic medical technologies.

At the invitation of the conference organizers, Jiangsu Xihong Biopharma Co., Ltd., a company focused on the research, development, and manufacturing of Class III regenerative aesthetic injectables, participated in the exhibition. The company showcased its core technological reserves, extensive production line layout, and substantial production capacity in the field of regenerative aesthetics, attracting significant attention from industry experts and peers.

At this conference, Xihong Biopharma’s portfolio drew significant industry attention, particularly its regenerative materials represented by poly-L-lactic acid (hereinafter referred to as “PLLA”) and polycaprolactone (hereinafter referred to as “PCL”). These materials achieve facial rejuvenation by stimulating the body’s own fibroblasts and collagen regeneration. Since 2021, three “regenerative” injectable products have been successively approved for market launch in China, propelling the country’s medical aesthetics anti-aging market from the “filler era” into the “regenerative era.”

According to 2020 data from the International Society of Aesthetic Plastic Surgery (ISAPS), the volume of regenerative aesthetic procedures, represented by poly-L-lactic acid (PLLA), increased by 34.2% year-on-year, leading the injectable aesthetics market. Additionally, data from Frost & Sullivan indicates that the market size for PLLA-based dermal fillers in China was RMB 111 million in 2021, and is projected to reach RMB 4 billion by 2030, signaling robust future growth for China’s regenerative aesthetics sector.

From another perspective, although the market is growing rapidly, domestic regenerative medical aesthetic products are still in their infancy. Currently, only three products have been approved, indicating significant potential for market penetration and future growth. In the future, with the rapid influx of technology, capital, and industrial resources, the indications for regenerative treatments, product availability across different price segments, and accessibility are bound to experience sustained and rapid development.

From a policy perspective, the “Outline of the 14th Five-Year Plan and Long-Range Objectives Through the Year 2035” explicitly identifies regenerative medicine, synthetic biology, and biopharmaceuticals as frontier scientific and technological areas requiring breakthroughs. The research, development, and application of bio-based and biomedical materials are cited as one of the measures to enhance the core competitiveness of the manufacturing sector. The Chinese government has consistently maintained a proactive and encouraging stance toward the R&D and application of novel biomedical materials, including those in regenerative medicine.

The Principle of Benefit Lies in Advancing with the Times. Since its establishment, Jiangsu Xihong Biopharma Co., Ltd. has been fully committed to building a research and development and manufacturing center for regenerative aesthetic materials. Currently, its investigational Class III regenerative aesthetic injectable based on poly-L-lactic acid (PLLA), commonly known as “Baby Face Needle,” has entered pivotal clinical trials. Utilizing a patented microsphere fabrication process, the product yields uniform and regular microspheres that distribute evenly within the tissue. It is administered via injection into the deep dermis and superficial subcutaneous layers to correct moderate to severe nasolabial fold wrinkles, demonstrating excellent clinical performance.

In addition, Xihong Youmei, Xihong Zhuyan, Xihong Huanyan, Xihong Suyan, and Xihong Liyan—cutting-edge anti-aging products—have also entered clinical trial stages. These products involve different novel materials, distinct technical features, varied efficacy profiles, and diverse market positioning. By leveraging the rigorous innovation characteristic of pharmaceutical enterprises, we are building a comprehensive and professional portfolio of medical aesthetic anti-aging solutions. This strategy aims to rapidly achieve product launch and market coverage in response to the trend of diversified and evolving market demands, thereby helping more beauty seekers achieve natural, safe, and long-lasting anti-aging results.

Meanwhile, based on market feedback regarding its marketed products, JIANGSU XIHONG BIOPHARMA CO.LTD has continuously achieved breakthroughs and improvements in microsphere technology innovation, new material modification and development, cross-linking technology development, and the development of hybrid gel-microsphere technologies. These efforts have effectively ensured the continuous rollout of new products and technologies, thereby steadily advancing the clinical registration and commercial launch of its product portfolio.

Leveraging its extensive technological reserves and robust R&D capabilities in the field of regenerative medical aesthetics, Jiangsu Xihong Biopharma Co., Ltd. has entered into deep strategic collaborations with CMS Pharmaceutical Group and So-Young Technology this year. These partnerships are injecting strong momentum into Xihong Biopharma’s continued investment in scientific research, in-depth strategic layout, and accelerated translation of research achievements in the regenerative medical aesthetics sector.

As an international congress centered on the concept of global anti-aging management, this year’s AMWC has delivered to China’s medical aesthetics industry a premier industry event integrating cutting-edge international anti-aging philosophies, technological innovations, and emerging themes.

Looking ahead, against the backdrop of an expanding market and increasingly standardized industry practices, Jiangsu Xihong Biopharma Co., Ltd. will remain true to its original mission. Guided by market demands and underpinned by technological innovation, we will drive R&D innovation, collaborate with partners to harness collective momentum, unlock greater possibilities in regenerative anti-aging, and jointly create a promising future for regenerative aesthetic medicine!